Sorry!! The article you are trying to read is not available now.
Regeneron, Sanofi Take Step Forward With Cholesterol Drug
MINYANVILLE ORIGINAL Highlighting their lead in a race to bring a new heart treatment to market Regeneron Pharmaceuticals (NASDAQ:REGN) and partner Sanofi (NYSE:SNY) said Monday that they are enrolling 18 000 patients in a late-stage clinical trial to further test an injected drug aimed at lowering bad cholesterol known as LDL. The drug part of a new class of medicines would treat people who can’t lower their LDL (low-density lipoprotein) cholesterol by taking widely used statin medicines like Pfizer’s (NYSE:PFE) Lipitor Merck’s (NYSE:MRK) Zocor or generic rivals. Regeneron and Sanofi are in a race with other companies including Amgen ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here